Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06441643 | Next Generation Rocklatan | PHASE2 | COMPLETED | 426 | — | — | Sep 4, 2024 | Nov 14, 2025 | Nov 18, 2025 | 12 | United States |
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements.
| Arm | Type | Description |
|---|---|---|
| AR-17043 low concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 medium concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 high concentration (Stage 1) | EXPERIMENTAL | AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| AR-17043 vehicle (Stage 1) | PLACEBO_COMPARATOR | AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| Rhopressa (Stage 1) | ACTIVE_COMPARATOR | Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
| PG043 low concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| PG043 high concentration (Stage 2) | EXPERIMENTAL | PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| AR-17043 high concentration (Stage 2) | ACTIVE_COMPARATOR | AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Latanoprost (Stage 2) | ACTIVE_COMPARATOR | Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Rocklatan (Stage 2) | ACTIVE_COMPARATOR | Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
| Name | Type | Description |
|---|---|---|
| AR-17043 Ophthalmic Solution | DRUG | Investigational monotherapy supplied in three concentration levels: low, medium, high |
| PG043 Ophthalmic Solution | DRUG | Investigational fixed dose combination supplied in two concentration levels: low and high |
| Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02% Ophthalmic Solution | DRUG | Marketed monotherapy |
| Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution | DRUG | Marketed fixed dose combination |
| AR-17043 Vehicle | DRUG | Placebo comparator |
Stage 1 Key Inclusion Criteria; * Diagnosis of OAG or OHT in both eyes. * High unmedicated IOP measurements in the study eye as specified in the protocol. * Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye. * Other prot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |